Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma
Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma
复制标题
DOI：
10.1002/cncr.10685
复制
发表时间：
2002-08-01
期刊：
影响因子：
6.2
通讯作者：
Polsky, D
中科院分区：
文献类型：
--
作者：
Hazan, C;Melzer, K;Polsky, D
背景识别Ki-67抗原的增殖标记物MIB-1在几种肿瘤类型中提供独立的预后信息。其在黑色素瘤中的效用主要在厚原发性肿瘤的研究中进行评估。它的有用性在较薄的病变还没有得到充分assessed.METHODS，一个很好的特点队列的137例患者诊断为原发性皮肤黑色素瘤在纽约大学医学院在1972年和1982年之间进行了研究的基础上提供的代表性组织和足够的临床随访唇。21例肿瘤厚度小于或等于1.0 mm，94例厚度在1.01和4.0 mm之间，22例厚度大于4.0 mm。使用单克隆抗体MIB-1通过免疫组织化学评估肿瘤细胞增殖。MIB-1表达与基线临床病理参数以及复发率（RR）、无病生存率（DFS）和总生存率（OS）相关。存活者的中位随访时间为6.5年（范围：5.6-17.5年）。高增殖指数，定义为20%或更多的肿瘤细胞显示核免疫反应性，观察到65例（47.4%）。高增殖指数与肿瘤厚度（P < 0.001）和分期（P = 0.03）显著相关。在原发性肿瘤溃疡（P = 0.09）、男性（P = 0.06）和DFS缩短（P = 0.12）中观察到接近统计学显著性的趋势。高增殖指数与RR或OS之间无显著相关性。在多变量分析中，肿瘤厚度是临床结局的最强预测因子。在原发性皮肤黑色素瘤中，高增殖指数与预测较差临床结果的临床病理参数相关。然而，它不是临床结果的独立预测因素。(C)2002年美国癌症协会。
BACKGROUND. The proliferation marker MIB-1, which recognizes the Ki-67 antigen, provides independent prognostic information in several tumor types. Its utility in melanoma has been evaluated mostly in studies of thick primary tumors. Its usefulness in thinner lesions has not been assessed adequately.METHODS, A well characterized cohort of 137 patients diagnosed with primary cutaneous melanoma at the New York University School of Medicine between 1972 and 1982 was studied based on the availability of representative tissues and adequate clinical follow-Lip. Twenty-one tumors were less than or equal to 1.0 mm thick, 94 were between 1.01 and 4.0 mm thick, and 22 were thicker than 4.0 mm. Tumor cell proliferation was assessed by immunohistochemistry using the monoclonal antibody MIB-1. MIB-1 expression was correlated with baseline clinicopathologic parameters, as well as recurrence (RR), disease-free (DFS), and overall survival (OS) rates. Median follow-up among survivors was 6.5 years (range, 5.6-17.5).RESULTS. High proliferative index, defined as 20% or more of tumor cells showing nuclear immuno reactivity, was observed in 65 of 137 (47.4%) cases. High proliferative index was significantly correlated with increased tumor thickness (P < 0.001) and higher stage (P = 0.03). Trends approaching statistical significance were observed with ulceration of the primary tumor (P = 0.09), male gender (P = 0.06), and shorter DFS (P = 0.12). No significant associations were seen between high proliferative index and RR or OS. In multivariate analyses, tumor thickness was the strongest predictor of clinical outcome.CONCLUSIONS. in primary cutaneous melanoma, a high proliferative index is associated with clinicopathologic parameters predictive of worse clinical outcomes. However, it was not an independent predictor of clinical outcome. (C) 2002 American Cancer Society.